Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APOL1 | O14791 | 8/20 | 0.48 |
| ▸ | CCR2 | P41597 | 3/20 | 0.45 |
| ▸ | MC4R | P32245 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | FPR1 | P21462 | 2/20 | 0.39 |
| ▸ | FPR2 | P25090 | 2/20 | 0.39 |
| ▸ | TACR2 | P21452 | 1/20 | 0.39 |
| ▸ | TACR1 | P25103 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5777123 | 0.82 | HPGD (0.50) | RAB9AALDH1A1 | |
| SCHEMBL5774126 | 0.81 | MEN1 (0.43) | RAB9AALDH1A1 | |
| SCHEMBL5775136 | 0.76 | BACE1 (0.47) | RAB9A | |
| SCHEMBL5774834 | 0.74 | MAPT (0.45) | ALDH1A1 | |
| SCHEMBL5776115 | 0.73 | LMNA (0.56) | RAB9AALDH1A1 | |
| SCHEMBL5769962 | 0.72 | SMN1; SMN2 (0.41) | RAB9AALDH1A1 | |
| SCHEMBL5773998 | 0.71 | FFAR1 (0.46) | ALDH1A1 | |
| SCHEMBL26583882 | 0.71 | APOL1 (0.66) | APOL1 | |
| SCHEMBL26583881 | 0.71 | APOL1 (0.66) | APOL1 | |
| SCHEMBL26584239 | 0.71 | APOL1 (0.66) | APOL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060084690-A1 | Isoxazole derivatives | MOMOSE YU | 2006-04-20 | — | — | US | disclosed |
| US-7022725-B2 | Isoxazole derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-04-04 | — | — | US | disclosed |
| US-20040048908-A1 | Isoxazole derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-03-11 | — | — | US | disclosed |
| EP-1340749-A1 | ISOXAZOLE DERIVATIVES | Takeda Chemical Industries, Ltd. (JP) | 2003-09-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084690-A1 | Isoxazole derivatives | INSR, GPR119, INSRR | APOL1 1314/4885CCR2 3524/4885MC4R 396/4885 |
| US-20040048908-A1 | Isoxazole derivatives | GPR119, INSR, IRS1 | APOL1 1743/4885CCR2 3629/4885MC4R 405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.